AngioDynamics Announces a Partnerships in Clinical Trial Engagements (PCTE) Initiative

Updated on March 11, 2023

AngioDynamics introduces a new grant opportunity that encourages clinical trial sites to build partnerships within underserved communities to increase patient participation.

AngioDynamics, Inc., a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life, today announced its Partnerships in Clinical Trial Engagements (PCTE) initiative.

The PCTE initiative aims to increase patient involvement in clinical trials in underrepresented communities by offering grants to healthcare providers. These grants will further develop relationships or programs that aim to advance healthcare by producing more inclusive clinical trial data. AngioDynamics is committed to educating key constituencies about the current clinical study landscape and addressing disparities in healthcare through this PCTE initiative. The PCTE initiative emphasizes building mutually beneficial relationships between healthcare providers and underrepresented patient populations. Through this collaboration, solutions will be developed to advance health equity.

“We believe every patient deserves access to quality care, and clinical trials should reflect the diversity of society,” said Juan Carlos Serna, Sr. VP, Scientific & Clinical Affairs. “Our PCTE initiative is our commitment to ensuring everyone has an equal chance to participate in important studies.”

AngioDynamics is currently enrolling patients in three separate US IDE clinical studies. The PRESERVE study for the treatment of prostate cancer with the NanoKnife System, the APEX-AV study for the treatment of pulmonary embolism with our AlphaVac F18*85 System, and the DIRECT study for the treatment of pancreatic cancer with the NanoKnife System.

Learn more about the Partnerships in Clinical Trial Engagements at

The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. Visit for full product information.

Visit for risk information. The NanoKnife System has been cleared by the FDA for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.

The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.